DDrare: Database of Drug Development for Rare Diseases

3. 脊髄性筋萎縮症
［臨床試験数：179，薬物数：102（DrugBank：26），標的遺伝子数：52，標的パスウェイ数：78］

Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2011-2012 seasonal flu vaccine Intramuscular; 2011-2012 seasonal flu vaccine Subcutaneous; 4-Aminopyridine; 4-aminopyridine; 4-cholesten-3-one, oxime; 4-cholesten-3-one,oxime; AVXS-101; AVXS-101 (previously known as scAAV9.CB.SMN); Adipose derived mesenchymal stem cell; Air; Amifampridine; Amifampridine Phosphate; Amifampridine Phosphate 10 MG Oral Tablet; Biocarn; Branaplam; Celecoxib; GH; HUMAN ANTI-PROMYOSTATIN MONOCLONAL ANTIBODY; Hydroxyurea; ISIS 396443; ISIS 396443 (BIIB058); ISIS 396443, BIIB058; Itraconazole; LEVOCARNITINE; LMI070; Leuprolide; Levocarnitine; Mestinon; Midazolam; N.a.; NUSINERSEN; NUSINERSEN SODIUM; Nerve Growth Factor; Norditropin SimpleXx; Norditropin SimpleXx 15 mg/1.5 ml; Nursinersen; Nusinersen; Nusinersen Injectable Product; Nusinersen Treatments; OLESOXIME; ONASEMNOGENE ABEPARVOVEC; Olesoxime; Onasemnogene Abeparvovec-xioi; Onasemnogene abeparvovec; Onasemnogene abeparvovec-xioi; Orfiril Saft; Other: Monthly assessments of functional motor abilities by a trained therapist; Other: Prospective observational registry; PARACETAMOL; Paracetamol; Paracetamol 120Mg/5mL Oral Suspension; Phenylbutyrate; Phosphate; Placebo; Procedure: Air stacking manuever; Procedure: Sham Procedure; Procedure: Sham procedure; Pyridostigmine; Pyridostigmine Bromide; Pyridostigmine bromide; RO6885247; RO6885247/F02; RO6885247/F03; RO7034067; RO7034067 / F12; RO7034067 / F13; RO7034067/F06 + solvente (RO; RO7034067/F06 with solvent (RO7034067/F08); RO7034067/F07 + solvente (RO; RO7034067/F07 with solvent (RO7034067/F09); RO7034067/F12; RO7034067/F13; RO7090919; RVG 03820; Reldesemtiv; Reldesemtiv 150 mg; Reldesemtiv 450 mg; Riluzole; Risdiplam; SESAME OIL, REFINED; SMART; SRK-015; Salbutamol; Sesame oil; Sodium phenylbutyrate; Sodium phenylbutyrate (NaPB); Somatotropin; Somatropin; Spinraza; Survival of Motor Neuron 2 (SMN2) Splicing Modulator Antisense Oligonucleotide; TRO19622; Testosterone; VALPROATE SODIUM; VOLMAX*30CPR 4MG R.P.; VPA; Valproate; Valproate, Levocarnitine; Valproic Acid; Valproic Acid (VPA); Valproic Acid and Levocarnitine; Valproic acid; Zolgensma

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01671384 (ClinicalTrials.gov)	August 2013	13/8/2012	Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years	Spinal Muscular Atrophy	Drug: Valproate , Levocarnitine;Drug: Placebo	All India Institute of Medical Sciences, New Delhi	NULL	Recruiting	2 Years	15 Years	Both	60	Phase 3	India
2	EUCTR2008-003915-11-DE (EUCTR)	24/09/2009	25/06/2009	Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I	Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I	Spinal Muscular Atrophy Type I in infants MedDRA version: 9.1;Level: LLT;Classification code 10051203;Term: Spinal muscular atrophy congenital	Trade Name: Orfiril Saft INN or Proposed INN: VALPROATE SODIUM Trade Name: Biocarn INN or Proposed INN: LEVOCARNITINE	University of Utah	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 1;Phase 2	Germany
3	NCT00661453 (ClinicalTrials.gov)	April 2008	14/4/2008	CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I	Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)	Spinal Muscular Atrophy Type I	Drug: Valproic Acid and Levocarnitine	University of Utah	Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.	Completed	N/A	12 Months	All	40	Phase 1;Phase 2	United States;Canada;Germany
4	NCT00227266 (ClinicalTrials.gov)	September 2005	23/9/2005	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)	Spinal Muscular Atrophy	Drug: Valproic Acid and Levocarnitine;Drug: Placebo	University of Utah	Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.;Abbott	Completed	2 Years	17 Years	All	94	Phase 2	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01671384
(ClinicalTrials.gov)

August 2013

13/8/2012

Valproate and Levocarnitine in Children With Spinal Muscular Atrophy

Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years

Spinal Muscular Atrophy

Drug: Valproate , Levocarnitine;Drug: Placebo

All India Institute of Medical Sciences, New Delhi

NULL

Recruiting

2 Years

15 Years

Both

Phase 3

India

EUCTR2008-003915-11-DE
(EUCTR)

24/09/2009

25/06/2009

Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I) - CARNI-VAL Type I

Spinal Muscular Atrophy Type I in infants
MedDRA version: 9.1;Level: LLT;Classification code 10051203;Term: Spinal muscular atrophy congenital

Trade Name: Orfiril Saft
INN or Proposed INN: VALPROATE SODIUM
Trade Name: Biocarn
INN or Proposed INN: LEVOCARNITINE

University of Utah

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Germany

NCT00661453
(ClinicalTrials.gov)

April 2008

14/4/2008

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)

Spinal Muscular Atrophy Type I

Drug: Valproic Acid and Levocarnitine

University of Utah

Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.

Completed

N/A

12 Months

All

Phase 1;Phase 2

United States;Canada;Germany

NCT00227266
(ClinicalTrials.gov)

September 2005

23/9/2005

Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy

Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)

Spinal Muscular Atrophy

Drug: Valproic Acid and Levocarnitine;Drug: Placebo

University of Utah

Families of Spinal Muscular Atrophy;Leadiant Biosciences, Inc.;Abbott

Completed

2 Years

17 Years

All

Phase 2

United States;Canada